---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-02-20T14:57:14.855409'
end_time: '2026-02-20T15:04:02.466298'
duration_seconds: 407.61
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: SCG5
  gene_symbol: SCG5
  uniprot_accession: P05408
  protein_description: 'RecName: Full=Neuroendocrine protein 7B2; AltName: Full=Pituitary
    polypeptide; AltName: Full=Secretogranin V; AltName: Full=Secretogranin-5; AltName:
    Full=Secretory granule endocrine protein I; Contains: RecName: Full=N-terminal
    peptide; Contains: RecName: Full=C-terminal peptide; Flags: Precursor;'
  gene_info: Name=SCG5; Synonyms=SGNE1;
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the 7B2 family. .
  protein_domains: Secretogranin_V. (IPR007945); Secretogranin_V (PF05281)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 19
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P05408
- **Protein Description:** RecName: Full=Neuroendocrine protein 7B2; AltName: Full=Pituitary polypeptide; AltName: Full=Secretogranin V; AltName: Full=Secretogranin-5; AltName: Full=Secretory granule endocrine protein I; Contains: RecName: Full=N-terminal peptide; Contains: RecName: Full=C-terminal peptide; Flags: Precursor;
- **Gene Information:** Name=SCG5; Synonyms=SGNE1;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the 7B2 family. .
- **Key Domains:** Secretogranin_V. (IPR007945); Secretogranin_V (PF05281)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "SCG5" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'SCG5' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **SCG5** (gene ID: SCG5, UniProt: P05408) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P05408
- **Protein Description:** RecName: Full=Neuroendocrine protein 7B2; AltName: Full=Pituitary polypeptide; AltName: Full=Secretogranin V; AltName: Full=Secretogranin-5; AltName: Full=Secretory granule endocrine protein I; Contains: RecName: Full=N-terminal peptide; Contains: RecName: Full=C-terminal peptide; Flags: Precursor;
- **Gene Information:** Name=SCG5; Synonyms=SGNE1;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the 7B2 family. .
- **Key Domains:** Secretogranin_V. (IPR007945); Secretogranin_V (PF05281)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "SCG5" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'SCG5' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **SCG5** (gene ID: SCG5, UniProt: P05408) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Gene functional annotation research report: Human SCG5 (UniProt P05408; neuroendocrine protein 7B2 / secretogranin V)

1. Target verification (critical identity check)

The target protein is human neuroendocrine protein 7B2, encoded by SCG5 (also referred to as secretogranin V/secretogranin-5), and is described in the literature explicitly as the “essential PC2 cofactor neuroendocrine protein 7B2 (7B2; gene SCG5)” in human pancreatic islets. (ramzy2020revisitingproinsulinprocessing pages 9-13)

Multiple sources further confirm that 7B2 is a neuroendocrine secretory-pathway protein that functions as a chaperone and endogenous inhibitor for prohormone convertase PC2 (PCSK2), and is widely discussed under the SCG5/7B2 synonymy in endocrine and neuroendocrine contexts. (kikuchi2025expressiondiversityin pages 24-25)

2. Key concepts and current understanding (definitions, molecular function, and mechanism)

2.1. What kind of protein is SCG5/7B2?

SCG5/7B2 is a neuroendocrine secreted chaperone protein, enriched in neuroendocrine tissues including pituitary, brain, pancreas, and adrenal, and concentrated in regulated secretory granules from which it can be released upon stimulation. (chaplot2020secretedchaperonesin pages 10-11)

It is also described as a sulfated protein synthesized as a precursor and proteolytically processed by a ubiquitous furin-like convertase (i.e., in the secretory pathway). (kikuchi2025expressiondiversityin pages 24-25)

2.2. Primary molecular function: chaperone/cofactor for PC2 (PCSK2) and regulator of its activity

The central, best-established function of SCG5/7B2 is to support the maturation and activity regulation of prohormone convertase 2 (PC2; PCSK2). Specifically, 7B2 binds PC2/proPC2 and is required for enzymatic activation of proPC2; it transiently interacts with proPC2 in the secretory pathway and binds specifically to PC2. (kikuchi2025expressiondiversityin pages 24-25, kikuchi2025expressiondiversityin pages 22-24)

In addition to supporting PC2 maturation/activation, 7B2 can act as an inhibitor of PC2 via its C-terminal peptide: the C-terminal peptide of 7B2 can potently inhibit PC2 in vitro, and mechanistic work indicates this suppression involves PC2/proPC2 regions (including interactions with the pro-domain). (kikuchi2025expressiondiversityin pages 24-25, kikuchi2025expressiondiversityin pages 22-24)

2.3. Processing/cleavage products of 7B2 (SCG5)

A key concept in 7B2 biology is regulated proteolytic processing. Full-length 7B2 (~27 kDa) is cleaved by the Golgi-resident convertase furin to yield a ~21 kDa product; both forms contain a central intrinsically disordered region (IDR). (chaplot2020secretedchaperonesin pages 10-11)

This processing helps separate functional regions, consistent with the notion that 7B2 contains distinct segments responsible for chaperone-like activity vs. inhibitory activity (e.g., C-terminal peptide inhibitory effects on PC2). (chaplot2020secretedchaperonesin pages 10-11, kikuchi2025expressiondiversityin pages 24-25)

2.4. Chaperone-like activity beyond PC2 (extracellular proteostasis concept)

Beyond being a PC2 cofactor, 7B2 is increasingly discussed as a secreted chaperone that may participate in extracellular proteostasis. A review focused on secreted chaperones in neurodegeneration describes 7B2 as one of a small set of neuronal proteins packaged with neuropeptides and released during synaptic activity, with potential client binding influenced by its intrinsically disordered region and oligomerization behavior. (chaplot2020secretedchaperonesin pages 10-11)

Human-islet-focused work further notes prior reports that 7B2 suppresses aggregation/cytotoxicity for amyloidogenic peptides (β-amyloid, synuclein, and islet amyloid polypeptide/IAPP) in culture, supporting a broader chaperone-like role not strictly limited to PC2 maturation. (ramzy2020revisitingproinsulinprocessing pages 13-17)

3. Subcellular localization and where SCG5 acts

3.1. Secretory pathway and regulated secretory granules

SCG5/7B2 is concentrated in regulated secretory granules and can be released upon stimulation, consistent with its role in endocrine/neuroendocrine peptide processing and regulated secretion. (chaplot2020secretedchaperonesin pages 10-11)

It also participates in secretory-pathway processing: furin cleavage is described as Golgi-resident, placing key maturation events in the Golgi/trans-Golgi network before granule residence and regulated release. (chaplot2020secretedchaperonesin pages 10-11)

3.2. Cell-type localization in human pancreatic islets (α-cells vs β-cells)

In human islets, 7B2 immunoreactivity is detectable in both α- and β-cells, but the intensity is lower in β-cells (contrasting with mice where α and β immunoreactivity is reported to be similar). (ramzy2020revisitingproinsulinprocessing pages 9-13, ramzy2020revisitingproinsulinprocessing pages 13-17)

These conclusions are supported by immunofluorescence images and quantification (alpha-cell to beta-cell intensity ratio for 7B2 in human vs mouse) from the same study’s figures. (ramzy2020revisitingproinsulinprocessing media 8799e6ec, ramzy2020revisitingproinsulinprocessing media defcd976, ramzy2020revisitingproinsulinprocessing media 5e5b3225, ramzy2020revisitingproinsulinprocessing media 324925e1, ramzy2020revisitingproinsulinprocessing media ff79e625)

3.3. Relationship to PC2 localization

PC2 protein and PCSK2 mRNA localize primarily to human α-cells, and PC2 immunoreactivity is not detected (or nearly undetectable) in human β-cells in the referenced human pancreas analyses. (ramzy2020revisitingproinsulinprocessing pages 9-13)

Consistent with this, functional pulse–chase experiments show that PC2 inhibition nearly blocks glucagon production, but does not significantly impair proinsulin processing in human islets, reinforcing that the major physiological PC2-dependent processing step in human islets is proglucagon→glucagon in α-cells rather than β-cell proinsulin maturation. (ramzy2020revisitingproinsulinprocessing pages 9-13)

4. Pathways and biological processes

4.1. Prohormone/neuropeptide processing pathway via PC2 (PCSK2)

PC2 (PCSK2) is one of the prohormone convertases involved in processing neuropeptide and hormone precursors; SCG5/7B2 is required for PC2 activation and modulates PC2 activity via its C-terminal inhibitory peptide. Thus, SCG5 is positioned as a key regulator of neuroendocrine prohormone processing capacity through the PC2 arm of the proprotein convertase network. (kikuchi2025expressiondiversityin pages 24-25, kikuchi2025expressiondiversityin pages 22-24)

4.2. ACTH/POMC axis implications (primarily supported by genetic models)

Work summarized in a histochemistry-focused paper cites genetic evidence from PC2 and 7B2 null mice analyzing POMC-derived peptide biosynthesis, and notes that 7B2 deficiency can lead to excessive ACTH secretion and lethal phenotypes that can be rescued by adrenalectomy, highlighting a critical in vivo role for 7B2-regulated peptide hormone systems. (kikuchi2025expressiondiversityin pages 25-26, kikuchi2025expressiondiversityin pages 26-26)

Although these are mouse model findings, they help define the conserved physiological systems most sensitive to 7B2/SCG5 loss (POMC/ACTH processing and secretion). (kikuchi2025expressiondiversityin pages 25-26)

5. Recent developments (prioritizing 2023–2024)

5.1. 2023: Astrocyte secretome and Alzheimer’s-relevant extracellular context

A 2023 astrocyte secretome proteomics study (bioRxiv preprint; posted 2023-01-18; https://doi.org/10.1101/2023.01.18.523916) reports that secretogranin 5 (SCG5; termed SECG5/SCG5 in the text) is among proteins discussed with reported chaperone activity and notes that an Aβ-chaperone function has been reported for SECG5. The authors report decreased secretion of SCG5 in astrocytes exposed to Aβ oligomer-containing medium, and place SCG5 among proteins that have been observed as altered in Alzheimer’s disease cerebrospinal fluid (CSF) in prior proteomic studies. (matafora2023proteomicsofthe pages 6-8)

The same study states that SCG5 has been repeatedly identified in AD vs control CSF studies (noted as present in 4 of 10 studies reviewed in their analysis) and discusses chromogranins/secretogranins as proposed AD biomarkers with decreased CSF levels. (matafora2023proteomicsofthe pages 8-10)

Interpretation: this line of evidence does not redefine SCG5’s canonical intracellular role (PC2 chaperone/inhibitor), but it reinforces the “secreted chaperone/extracellular proteostasis” framing, and motivates interest in SCG5 as a CNS biofluid biomarker candidate in neurodegeneration research. (matafora2023proteomicsofthe pages 6-8, matafora2023proteomicsofthe pages 8-10)

5.2. 2024: Human CF-related diabetes (CFRD) spatial transcriptomics

A 2024 Scientific Reports study (published Oct 2024; https://doi.org/10.1038/s41598-024-76722-1) analyzing human pancreas using spatial transcriptomics reports SCG5 downregulation in both α- and β-cells in cystic fibrosis-related diabetes (CFRD) relative to controls. The authors explicitly connect SCG5/7B2 to its known PC2 chaperone role and hypothesize that reduced SCG5 could impair proglucagon→glucagon processing and processing of islet amyloid polypeptide, thereby contributing to islet dysfunction. (gharib2024cysticfibrosisrelateddiabetes pages 8-9)

Interpretation: this represents a recent application of high-dimensional tissue profiling to place SCG5 within cell-type-specific islet transcriptional programs in a real-world disease context, although quantitative fold-changes and statistical values for SCG5 are referenced as being in supplemental tables rather than shown in the excerpt. (gharib2024cysticfibrosisrelateddiabetes pages 8-9)

6. Current applications and real-world implementations

6.1. Biomarker research (CSF / secretome / neurodegeneration)

SCG5/7B2 is actively considered in biomarker discovery pipelines in neurodegeneration contexts due to its detectability in CSF and recurring identification in AD vs control CSF proteomics literature, as summarized in the 2023 astrocyte secretome study. (matafora2023proteomicsofthe pages 8-10)

A practical “implementation” angle is that SCG5 can be quantified by mass spectrometry in secretome/CSF proteomics workflows, and that cell-type secretion studies (e.g., astrocytes under Aβ stress) can be used to interpret potential tissue sources of biofluid markers. (matafora2023proteomicsofthe pages 6-8)

6.2. Endocrine/islet pathophysiology interpretation (human pancreas)

In endocrine biology and diabetes research, SCG5 is a tool for understanding PC2-dependent hormone processing. Human pancreas work indicates a strong α-cell localization of the PC2 pathway and confirms that PC2 inhibition affects glucagon production but not proinsulin processing in healthy human islets; these results motivate a human-specific revision of traditional rodent-based assumptions about insulin processing pathways. (ramzy2020revisitingproinsulinprocessing pages 9-13)

The 2024 CFRD spatial transcriptomics study further embeds SCG5 into disease-associated islet transcriptional dysregulation, offering a mechanistic hypothesis (impaired prohormone processing) that can be tested in future functional studies. (gharib2024cysticfibrosisrelateddiabetes pages 8-9)

7. Expert synthesis and analysis (authoritative interpretation)

7.1. Canonical functional “core”

Across endocrine and neurobiology literature, the most defensible core annotation for SCG5/7B2 is:

• A regulated secretory pathway protein (granule-enriched) that is processed by furin in the Golgi, and that chaperones proPC2/PCSK2 to enable its maturation/activation while also providing an inhibitory C-terminal peptide that can suppress PC2 activity. (chaplot2020secretedchaperonesin pages 10-11, kikuchi2025expressiondiversityin pages 24-25, kikuchi2025expressiondiversityin pages 22-24)

This “dual-function” model (facilitating PC2 maturation while enabling inhibition through its C-terminal peptide) is important for functional annotation because it explains why SCG5 is not simply an on/off switch but a regulator of convertase timing and activity in the secretory pathway. (kikuchi2025expressiondiversityin pages 24-25)

7.2. Human-specific context matters

Human islet biology differs from mouse: in humans, PC2 appears largely α-cell-restricted and β-cells can process proinsulin without PC2-dependent steps; 7B2 is present in β-cells but at lower immunoreactivity than α-cells. This suggests SCG5 in human β-cells may be serving functions beyond PC2 maturation (e.g., broader chaperone roles), or that PC2 expression is post-transcriptionally limited in β-cells. (ramzy2020revisitingproinsulinprocessing pages 9-13, ramzy2020revisitingproinsulinprocessing pages 13-17)

8. Relevant quantitative/statistical data points (as available in retrieved sources)

• CSF concentration: A review reports CSF levels of 7B2 of approximately 3 ng/mL (0.14 nM) and that levels decline with age. (chaplot2020secretedchaperonesin pages 10-11)

• Human islet processing dependence: In human islets, PC2 inhibition produces near total blockade of glucagon production but does not significantly change proinsulin processing in pulse–chase experiments. (ramzy2020revisitingproinsulinprocessing pages 9-13)

• Enzymology context: PC2 is noted to be ~80–100× more catalytically active than PC1/3 (as cited in the human islet study), which is relevant when interpreting why small amounts of PC2 could have outsized processing effects in cell types where it is present. (ramzy2020revisitingproinsulinprocessing pages 9-13)

• 2023 proteomics summary statistic: The 2023 astrocyte secretome study reports 45 proteins with altered secretion in response to Aβ oligomer-containing medium (23 up; 22 down), within which SCG5 is discussed in relation to chaperone activity and biomarker context, though the excerpt does not provide SCG5-specific fold-change statistics. (matafora2023proteomicsofthe pages 8-10)

9. Limitations of the current evidence base (important for functional annotation)

• Some of the mechanistic endocrine phenotypes summarized (e.g., lethality/ACTH axis changes) rely heavily on mouse genetic models and may not map one-to-one to human physiology, though the underlying PC2/7B2 interaction is considered conserved. (kikuchi2025expressiondiversityin pages 25-26, kikuchi2025expressiondiversityin pages 26-26)

• Recent 2023–2024 “omics” studies that mention SCG5 (astrocyte secretome; CFRD spatial transcriptomics) often emphasize global patterns; SCG5-specific quantitative performance (effect sizes, diagnostic AUCs, etc.) is not present in the excerpts retrieved here and may reside in supplementary tables or follow-up peer-reviewed articles. (gharib2024cysticfibrosisrelateddiabetes pages 8-9, matafora2023proteomicsofthe pages 8-10)

10. Key references (publication date + URL)

• Ramzy A, Asadi A, Kieffer TJ. “Revisiting Proinsulin Processing: Evidence That Human β-Cells Process Proinsulin With Prohormone Convertase (PC) 1/3 but Not PC2.” Diabetes. Published Apr 2020. https://doi.org/10.2337/db19-0276 (ramzy2020revisitingproinsulinprocessing pages 9-13)

• Chaplot K, Jarvela TS, Lindberg I. “Secreted Chaperones in Neurodegeneration.” Frontiers in Aging Neuroscience. Published Aug 2020. https://doi.org/10.3389/fnagi.2020.00268 (chaplot2020secretedchaperonesin pages 10-11)

• Matafora V et al. “Proteomics of the astrocyte secretome reveals changes in their response to soluble oligomeric Aβ.” bioRxiv preprint. Posted Jan 2023. https://doi.org/10.1101/2023.01.18.523916 (matafora2023proteomicsofthe pages 6-8)

• Gharib SA et al. “Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs.” Scientific Reports. Published Oct 2024. https://doi.org/10.1038/s41598-024-76722-1 (gharib2024cysticfibrosisrelateddiabetes pages 8-9)

Evidence-supported visual references

• Immunostaining panels and quantification for PC2 and 7B2/SCG5 in human vs mouse islets (from Ramzy et al. 2020 figures and supplemental figure crops). (ramzy2020revisitingproinsulinprocessing media 8799e6ec, ramzy2020revisitingproinsulinprocessing media defcd976, ramzy2020revisitingproinsulinprocessing media 5e5b3225, ramzy2020revisitingproinsulinprocessing media 324925e1, ramzy2020revisitingproinsulinprocessing media ff79e625)

References

1. (ramzy2020revisitingproinsulinprocessing pages 9-13): Adam Ramzy, Ali Asadi, and Timothy J. Kieffer. Revisiting proinsulin processing: evidence that human β-cells process proinsulin with prohormone convertase (pc) 1/3 but not pc2. Diabetes, 69:1451-1462, Apr 2020. URL: https://doi.org/10.2337/db19-0276, doi:10.2337/db19-0276. This article has 69 citations and is from a highest quality peer-reviewed journal.

2. (kikuchi2025expressiondiversityin pages 24-25): Shota Kikuchi, Seiji Torii, Masahiro Hosaka, Tadashi Yasui, and Hiroshi Gomi. Expression diversity in endocrine cells and between species revealed by novel synthetic peptide antibodies recognizing the neuroendocrine protein 7b2. Journal of Histochemistry &amp; Cytochemistry, 73(7–8):289-314, Aug 2025. URL: https://doi.org/10.1369/00221554251365996, doi:10.1369/00221554251365996. This article has 0 citations and is from a peer-reviewed journal.

3. (chaplot2020secretedchaperonesin pages 10-11): Kriti Chaplot, Timothy S. Jarvela, and Iris Lindberg. Secreted chaperones in neurodegeneration. Frontiers in Aging Neuroscience, Aug 2020. URL: https://doi.org/10.3389/fnagi.2020.00268, doi:10.3389/fnagi.2020.00268. This article has 64 citations and is from a peer-reviewed journal.

4. (kikuchi2025expressiondiversityin pages 22-24): Shota Kikuchi, Seiji Torii, Masahiro Hosaka, Tadashi Yasui, and Hiroshi Gomi. Expression diversity in endocrine cells and between species revealed by novel synthetic peptide antibodies recognizing the neuroendocrine protein 7b2. Journal of Histochemistry &amp; Cytochemistry, 73(7–8):289-314, Aug 2025. URL: https://doi.org/10.1369/00221554251365996, doi:10.1369/00221554251365996. This article has 0 citations and is from a peer-reviewed journal.

5. (ramzy2020revisitingproinsulinprocessing pages 13-17): Adam Ramzy, Ali Asadi, and Timothy J. Kieffer. Revisiting proinsulin processing: evidence that human β-cells process proinsulin with prohormone convertase (pc) 1/3 but not pc2. Diabetes, 69:1451-1462, Apr 2020. URL: https://doi.org/10.2337/db19-0276, doi:10.2337/db19-0276. This article has 69 citations and is from a highest quality peer-reviewed journal.

6. (ramzy2020revisitingproinsulinprocessing media 8799e6ec): Adam Ramzy, Ali Asadi, and Timothy J. Kieffer. Revisiting proinsulin processing: evidence that human β-cells process proinsulin with prohormone convertase (pc) 1/3 but not pc2. Diabetes, 69:1451-1462, Apr 2020. URL: https://doi.org/10.2337/db19-0276, doi:10.2337/db19-0276. This article has 69 citations and is from a highest quality peer-reviewed journal.

7. (ramzy2020revisitingproinsulinprocessing media defcd976): Adam Ramzy, Ali Asadi, and Timothy J. Kieffer. Revisiting proinsulin processing: evidence that human β-cells process proinsulin with prohormone convertase (pc) 1/3 but not pc2. Diabetes, 69:1451-1462, Apr 2020. URL: https://doi.org/10.2337/db19-0276, doi:10.2337/db19-0276. This article has 69 citations and is from a highest quality peer-reviewed journal.

8. (ramzy2020revisitingproinsulinprocessing media 5e5b3225): Adam Ramzy, Ali Asadi, and Timothy J. Kieffer. Revisiting proinsulin processing: evidence that human β-cells process proinsulin with prohormone convertase (pc) 1/3 but not pc2. Diabetes, 69:1451-1462, Apr 2020. URL: https://doi.org/10.2337/db19-0276, doi:10.2337/db19-0276. This article has 69 citations and is from a highest quality peer-reviewed journal.

9. (ramzy2020revisitingproinsulinprocessing media 324925e1): Adam Ramzy, Ali Asadi, and Timothy J. Kieffer. Revisiting proinsulin processing: evidence that human β-cells process proinsulin with prohormone convertase (pc) 1/3 but not pc2. Diabetes, 69:1451-1462, Apr 2020. URL: https://doi.org/10.2337/db19-0276, doi:10.2337/db19-0276. This article has 69 citations and is from a highest quality peer-reviewed journal.

10. (ramzy2020revisitingproinsulinprocessing media ff79e625): Adam Ramzy, Ali Asadi, and Timothy J. Kieffer. Revisiting proinsulin processing: evidence that human β-cells process proinsulin with prohormone convertase (pc) 1/3 but not pc2. Diabetes, 69:1451-1462, Apr 2020. URL: https://doi.org/10.2337/db19-0276, doi:10.2337/db19-0276. This article has 69 citations and is from a highest quality peer-reviewed journal.

11. (kikuchi2025expressiondiversityin pages 25-26): Shota Kikuchi, Seiji Torii, Masahiro Hosaka, Tadashi Yasui, and Hiroshi Gomi. Expression diversity in endocrine cells and between species revealed by novel synthetic peptide antibodies recognizing the neuroendocrine protein 7b2. Journal of Histochemistry &amp; Cytochemistry, 73(7–8):289-314, Aug 2025. URL: https://doi.org/10.1369/00221554251365996, doi:10.1369/00221554251365996. This article has 0 citations and is from a peer-reviewed journal.

12. (kikuchi2025expressiondiversityin pages 26-26): Shota Kikuchi, Seiji Torii, Masahiro Hosaka, Tadashi Yasui, and Hiroshi Gomi. Expression diversity in endocrine cells and between species revealed by novel synthetic peptide antibodies recognizing the neuroendocrine protein 7b2. Journal of Histochemistry &amp; Cytochemistry, 73(7–8):289-314, Aug 2025. URL: https://doi.org/10.1369/00221554251365996, doi:10.1369/00221554251365996. This article has 0 citations and is from a peer-reviewed journal.

13. (matafora2023proteomicsofthe pages 6-8): Vittoria Matafora, Alena Gorb, Wendy Noble, Angela Bachi, Beatriz Gomez Perez-Nievas, and Maria Jimenez-Sanchez. Proteomics of the astrocyte secretome reveals changes in their response to soluble oligomeric aß. bioRxiv, Jan 2023. URL: https://doi.org/10.1101/2023.01.18.523916, doi:10.1101/2023.01.18.523916. This article has 1 citations.

14. (matafora2023proteomicsofthe pages 8-10): Vittoria Matafora, Alena Gorb, Wendy Noble, Angela Bachi, Beatriz Gomez Perez-Nievas, and Maria Jimenez-Sanchez. Proteomics of the astrocyte secretome reveals changes in their response to soluble oligomeric aß. bioRxiv, Jan 2023. URL: https://doi.org/10.1101/2023.01.18.523916, doi:10.1101/2023.01.18.523916. This article has 1 citations.

15. (gharib2024cysticfibrosisrelateddiabetes pages 8-9): Sina A. Gharib, Rachna Vemireddy, Joseph J. Castillo, Brendy S. Fountaine, Theo K. Bammler, James W. MacDonald, Rebecca L. Hull-Meichle, and Sakeneh Zraika. Cystic fibrosis-related diabetes is associated with reduced islet protein expression of glp-1 receptor and perturbation of cell-specific transcriptional programs. Scientific Reports, Oct 2024. URL: https://doi.org/10.1038/s41598-024-76722-1, doi:10.1038/s41598-024-76722-1. This article has 8 citations and is from a peer-reviewed journal.

## Citations

1. ramzy2020revisitingproinsulinprocessing pages 9-13
2. kikuchi2025expressiondiversityin pages 24-25
3. chaplot2020secretedchaperonesin pages 10-11
4. ramzy2020revisitingproinsulinprocessing pages 13-17
5. kikuchi2025expressiondiversityin pages 25-26
6. matafora2023proteomicsofthe pages 6-8
7. matafora2023proteomicsofthe pages 8-10
8. gharib2024cysticfibrosisrelateddiabetes pages 8-9
9. kikuchi2025expressiondiversityin pages 22-24
10. kikuchi2025expressiondiversityin pages 26-26
11. https://doi.org/10.1101/2023.01.18.523916
12. https://doi.org/10.1038/s41598-024-76722-1
13. https://doi.org/10.2337/db19-0276
14. https://doi.org/10.3389/fnagi.2020.00268
15. https://doi.org/10.2337/db19-0276,
16. https://doi.org/10.1369/00221554251365996,
17. https://doi.org/10.3389/fnagi.2020.00268,
18. https://doi.org/10.1101/2023.01.18.523916,
19. https://doi.org/10.1038/s41598-024-76722-1,